Levothyroxine Sodium Tablets 25 mcg
Accord recalls Levothyroxine 25 mcg tablets due to subpotency.
Consumers who have the recalled Levothyroxine Sodium Tablets should stop using them and contact their healthcare provider for guidance. Return the product to the place of purchase or follow the recall instructions provided by Accord Healthcare.
Why it was recalled
Accord Healthcare is recalling Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 1000-count bottles, because the drug may be subpotent, which could lead to inadequate thyroid hormone replacement and potentially serious health consequences.
Is mine affected?
This recall covers 12 products. Check the NDC or UPC and strength printed on the package. Yours is affected if it matches one below.
Levothyroxine Sodium Tablets, USPLot code: 2026
| Strength | NDC / UPC | Recall # |
|---|---|---|
| 150 mcg | NDC 16729-455-17 | D-0783-2026 |
| 100 mcg | NDC 16729-451-15, NDC 16729-451-17 | D-0779-2026 |
| 200 mcg | NDC 16729-457-15, NDC 16729-457-17 | D-0785-2026 |
| 137 mcg | NDC 16729-454-15, NDC 16729-454-17 | D-0782-2026 |
| 25 mcg | NDC 16729-447-17 | D-0775-2026 |
| 112 mcg | NDC 16729-452-17 | D-0780-2026 |
| 300 mcg | NDC 16729-458-15 | D-0786-2026 |
| 50 mcg | NDC 16729-448-17 | D-0776-2026 |
Show all 12 products
| Strength | NDC / UPC | Recall # |
|---|---|---|
| 175 mcg | NDC 16729-456-15, NDC 16729-456-17 | D-0784-2026 |
| 125 mcg | NDC 16729-453-17 | D-0781-2026 |
| 75 mcg | NDC 16729-449-17 | D-0777-2026 |
| 88 mcg | NDC 16729-450-17 | D-0778-2026 |
Where it was sold
Distributed nationwide.
Timeline
- Firm initiated recall
- Publicly announced
- Listed on Recall Canary
- Summary updated
Official source
Other Drug Potency recalls
Other recent recalls from ACCORD HEALTHCARE, INC.
Editorial summary by Recall Canary · summary updated 2026-08-23 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification